There are 2867 resources available
1457P - A UK multicentre retrospective review of metastatic renal cell carcinoma (mRCC) patients (pts) outcomes with brain metastases (BM) in the modern era
Presenter: Gihan Ratnayake
Session: Poster session 17
1460P - IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany
Presenter: Guillaume Mouillet
Session: Poster session 17
1461P - Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
Presenter: Jonathan Thouvenin
Session: Poster session 17
1462P - Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
Presenter: Marco Stellato
Session: Poster session 17
1463P - Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review
Presenter: Amar Challapalli
Session: Poster session 17
1465P - Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United States
Presenter: Daniel Geynisman
Session: Poster session 17
1466P - Efficacy of immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC) venous tumor thrombus (VTT) shrinkage
Presenter: Jonathan Thouvenin
Session: Poster session 17